



an Open Access Journal by MDPI

Immune-Mediated Skin Diseases: From Pathophysiology to Novel Therapeutic Approaches

Guest Editors:

Dr. Anna Campanati

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy

Dr. Emanuela Martina

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy

Prof. Dr. Annamaria Offidani

Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy

Deadline for manuscript submissions:

closed (31 December 2021)



mdpi.com/si/76526

Message from the Guest Editors

Growing interest in the pathogenesis of immune-mediated skin diseases (skin IMIDs) has led to the identification of several inflammatory pathways that are crucial for their development and maintenance.

Dermatologists can be considered sentinel clinicians in the development of systemic involvement related to skin IMIDs, they can play a significant role in modifying the natural history of skin IMIDs through early recognition and therapeutic interventions.

In recent years, research has led to highly effective new treatment options, and others are expected in the near future. However, the following questions remain: What are the main pathological drivers of skin IMIDs? What is the role of the skin microenvironment? What are the mechanisms underlying systemic involvement in skin IMIDs? Are there predictive biomarkers for systemic targeted treatments? Can an early therapeutic intervention really change the natural history of skin IMIDs and their systemic repercussions?

This Special Issue intends to provide plausible answers to these and other questions by presenting the latest research on skin IMIDs, as well as highlighting research gaps that should be addressed in future studies.



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI